CHOOSE KCENTRA

Providing Proven Speed and Trusted Safety Since 2013

Trusted experience 10+ years in the US; #1 prescribed 4F-PCC

Lower all-cause mortality with comparable TE events vs
plasma²

Review the data

Faster Acting*

Superior INR reduction at 30 minutes after end of infusion vs plasma

EXPLORE KCENTRA VS PLASMA

Sustained INR Reduction^†

Statistically significant INR reduction sustained ≤1.3 for up to 8 or 12 hours vs plasma

INR REDUCTION DATA

Faster Administration & Lower Volume

Mean infusion time is under 25 minutes; ~85% less volume vs plasma^3,4

SEE SUPERIOR SPEED

*In 2 head-to-head trials, KCENTRA demonstrated superiority to plasma in 3 of 4 efficacy endpoints. Superior hemostatic efficacy in the Urgent Surgery/Invasive Procedures trial and equally effective hemostasis in the Acute Major Bleeding trial. Faster INR reduction (to ≤1.3 at 30 minutes after end of infusion) in both head-to-head trials.

^†8 hours for Urgent Surgery/Invasive Procedures trial and 12 hours for Acute Major Bleeding trial. Administer vitamin K concurrently to patients receiving KCENTRA. Vitamin K is administered to maintain vitamin K–dependent clotting factor levels once the effects of KCENTRA have diminished.